Icagen
|
Biotech Aldagen plans a stock offering: The Durham company files with SEC its intention to raise...
tmcnet.com May 13, 2008 1 related
KRT) Via Acquire Media NewsEdge) May 13--A small Durham biotechnology company has filed plans to sell stock to the public, taking a leap of faith that Wall Street is recuperating. Before the deal can happen, the number of shares for sale and the expected price per share must be determined and filed with...
Icagen to Present At the Rodman & Renshaw 5th Annual Global Healthcare Conference On May 19, 2008
primenewswire.com May 12, 2008
RESEARCH TRIANGLE PARK, N.C., May 12, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19 through May 20, 2008 at the Le Meridien Beach Plaza Hotel in Monte...
Aldagen plans IPO worth up to $80.5 million
newsobserver.com May 12, 2008 2 related
A small Durham biotechnology company is planning to sell stock to the public to raise as much as $80.5 million, according to a filing with the Securities and Exchange Commission. ... By Sabine Vollmer, Staff Writer A small Durham biotechnology company is planning to sell...
Icagen reports a smaller loss
newsobserver.com May 9, 2008
Icagen reported a smaller first-quarter loss Thursday, as the Durham company cut expenses after ending research studies on a failed treatment for sickle cell disease. ... Icagen continues to study promising treatments for other ailments but is years from winning...
Icagen Reports First Quarter 2008 Financial Results
primezone.com May 8, 2008 1 related
RESEARCH TRIANGLE PARK, N.C., May 8, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today its financial results and operational highlights for the first quarter ended March 31, 2008. For the first quarter of 2008, the Company reported revenues of $3.0 million and a net loss of $3.6...
Icagen reports narrower loss
newsobserver.com May 8, 2008
Icagen reported a smaller first-quarter loss this morning, as the Durham company cut expenses after ending research studies on a treatment for sickle cell disease. ... Icagen continues to study promising treatments for other ailments, including epilepsy and asthma, but...
Icagen to Announce First Quarter 2008 Results and Conduct Conference Call On May 8, 2008
primezone.com May 1, 2008
RESEARCH TRIANGLE PARK, N.C., May 1, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced it will release first quarter 2008 financial results on Thursday, May 8, 2008. The Company will also conduct a conference call that day at 10:00 a.m. Eastern Time to discuss results and...
University of London teams up with Pfizer and Icagen for pain research
pharmiweb.co.uk Apr 3, 2008
Science Business ... Science|Business The drug companies Pfizer Inc. and Icagen Inc. announced a collaboration with Birkbeck, University of London, to study the structural biology of sodium channels, the molecular gateways that regulate the signals of nerve cells. The...
Icagen and Pfizer Form Collaboration With Birkbeck, University of London to Elucidate Channel Struct
pharmiweb.co.uk Mar 24, 2008
Interest!ALERT ... RESEARCH TRIANGLE PARK, N.C., March 20, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. today announced that, together with Pfizer, it has entered into a collaboration with the laboratory of Professor B. A. Wallace at Birkbeck, University of London, to study the...
Icagen and Pfizer Form Collaboration With Birkbeck, University of London to Elucidate Channel...
primenewswire.com Mar 20, 2008 5 related
RESEARCH TRIANGLE PARK, N.C., March 20, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that, together with Pfizer, it has entered into a collaboration with the laboratory of Professor B. A. Wallace at Birkbeck, University of London, to study the structural biology of sodium...